Professor of Cardiology, Coronary and Structural Interventional Cardiologist, @SRIHER & @SRMC, Chennai. #tweetsaremyownviews
Chennai, India
Joined June 2016
- Tweets1.2K
- Following893
- Followers1.5K
- Likes1.9K
S Nagendra Boopathy retweeted
Expected vs Observed active control rate 6% vs 2.4%
NI margin 1.5% RD; 1.25 RR
Because observed rate was < expected, establishing NI using RR margin is more conservative.
HR: 0.86, 0.47-1.59
NI is not established!
No ancillary benefit for DCB!
Why accept any inferiority of DCB?
Results of TRANSFORMED II Trial:
Siroliumus coated balloons vs Everolimus
eluting stent in native coronary vessels:
#LBCT
⭐️ Sirolimus DCB non inferior to Everolimus DES for 12 month TLF
⭐️ Bail out stenting required in 7.6% patient assigned to DCB
⭐️ Any target vessel revascularization more frequent in DCB group.
#TCT2026 @TCTConference @crfheart
S Nagendra Boopathy retweeted
When a cath lab crisis hits, what should happen first? @MortonKern outlines practical steps for managing no-reflow, coronary perforation, acute vessel closure, & vascular access complications + who to call & communication under pressure. hubs.ly/Q04yB3XJ0 #cardiotwitter
S Nagendra Boopathy retweeted
Medicine and the Fight Against Death: A Journey of Success and Innovation!
#EHJ #aging #cure #genetics #cardiovascular #medicine #cardiotwitter @ESC_Journals @escardio
ow.ly/fyBg50ZRRnu
S Nagendra Boopathy retweeted
Incidence of refibrillation and shock-resistant ventricular fibrillation during OHCA when treated with a public access defibrillator: implications for CPR timing in lay rescuer-treated OHCA.@drkarthik2010 @BoopathyCardio @BelfastTrust
bit.ly/4dpHUDl
S Nagendra Boopathy retweeted
In this #JACCAsia editorial, the authors review the "SMuRF paradox" after #AMI.
Future risk stratification may require integrating traditional CV risk factors with inflammatory, genetic, & psychosocial markers. jacc.org/doi/10.1016/j.jacas…
#cvPrev #MACE @BoopathyCardio @harilalith
S Nagendra Boopathy retweeted
Effect of pictorial-based information about atherosclerosis on adherence to lifestyle recommendations: results from the VIPVIZA randomised controlled trial.
@BoopathyCardio @drkarthik2010 @LoginRajeevAgar @umeauniversity
bit.ly/4pD38Cl
S Nagendra Boopathy retweeted
Non-invasive diagnosis of left main coronary artery disease in chronic coronary syndrome patients: diagnostic utility of an approach using clinical and ECG stress testing
doi.org/10.1093/eurheartj/eh…
#CCS #CAD #LM #cardiotwitter @ESC_Journals @escardio
S Nagendra Boopathy retweeted
This article by @AndrewFoy82 is a must read for anyone in medicine. External validity of clinical trials may be one of the most under-appreciated concepts in medicine especially when it comes to heart failure therapy. open.substack.com/pub/sensib…
S Nagendra Boopathy retweeted
From humble beginnings to leading one of the nation's premier cardiovascular programs, Dr. Samin Sharma and I talk about the journey that shaped his career and what lies ahead in his new role as Chief of Cardiology at Mount Sinai.
clinicaltrialresults.org/fro…
S Nagendra Boopathy retweeted
Congratulations to Samin K. Sharma, MD, who has been appointed Chief of Clinical Cardiology at Mount Sinai Hospital in New York City.
S Nagendra Boopathy retweeted
Mineralocorticoid receptor antagonists in heart failure with sustained monomorphic ventricular tachycardia: comparative analysis of spironolactone versus eplerenone.@drkarthik2010 @BoopathyCardio @SanjitSJolly @hfaimedia
bit.ly/49qoex1
S Nagendra Boopathy retweeted
The ideal puncture site can be identified only by echo!!!!! I think that transesophageal or intracardiac #echofirst guidance should become the only way to perform transeptal puncture!
Where is the ideal site for transseptal puncture?
In the 40° RAO projection, a pigtail catheter placed in the non-coronary aortic cusp helps define the posterior border of the aortic root. The optimal puncture site (X) is typically located 1–3 cm inferior to the posterior boundary of the aortic root, within the fossa ovalis region.
Accurate localization is critical to safely access the left atrium while minimizing the risk of aortic puncture and other complications.
Reference: Croft CH, Lipscomb K. Modified technique of transseptal left heart catheterization. J Am Coll Cardiol. 1985;5(4):904–910.
S Nagendra Boopathy retweeted
A p-value below the noninferiority threshold is not a free pass. Noninferiority margins need clinical justification, and intention-to-treat and per-protocol analyses should ideally point in the same direction. As DES outcomes continue to improve, noninferiority trials of coronary devices become increasingly fragile.
S Nagendra Boopathy retweeted
Coronary microvascular obstruction: the "no-reflow" problem that haunts STEMI care. New ESC clinical consensus on pathophysiology, prevention & management: a must-read. Read more in #EHJ.
doi.org/10.1093/eurheartj/eh…
#cardiotwitter @ESC_Journals @escardio
S Nagendra Boopathy retweeted
A Mayo Clinic-developed artificial intelligence (AI) model can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible. The findings, published in Gut, mark a milestone in Mayo Clinic's multiyear research effort to enable earlier detection of one of the deadliest cancers.
Learn more: mayocl.in/4eippBP
S Nagendra Boopathy retweeted
Congratulations to Dr C Narasimhan sir for the Lifetime Achievement Award at the HRS 2026! Richly deserved for having pioneered EP & for inspiring & training so many cardiologists!
(Pic courtesy: @greatbong)
#cardiotwitter #epeeps
S Nagendra Boopathy retweeted
Combined effect of educational attainment and diabetes on 1-year all-cause mortality in heart failure patients: findings from the National Heart Failure Registry, India. @drkarthik2010 @BoopathyCardio @ICMRDELHI @hfai20 @dranulala @drambujroy @DrCNManjunath
bit.ly/4vuKHlS
S Nagendra Boopathy retweeted
Compilation of LBT’s into a single image for ease. Thank you @drhussnainsadiq for your work.
S Nagendra Boopathy retweeted
Finally published: the COBRRA trial, the first randomized head-to-head comparison of major DOACs — something the companies would never have done themselves, as a direct confrontation goes beyond their commercial interests. This was driven by independent investigators. The results somewhat support the idea of apixaban being the “safer” DOAC. That said, the list of study limitations is long, and for me, labeling something as “safe” is not enough — after all, even placebo is “safe” when it comes to bleeding. nejm.org/doi/full/10.1056/NE…
S Nagendra Boopathy retweeted
Impact of invasive coronary function testing on management of ANOCA
patients and secondary care resource utilisation: insights from a multicentre
retrospective study in the UK. @BHIBristol @RUHBath @drkarthik2010 @BoopathyCardio
bit.ly/4camSbZ
